Literature DB >> 17599006

Endogenous and exogenous vasopressin in shock.

Juan A Oliver1, Donald W Landry.   

Abstract

PURPOSE OF REVIEW: Vasopressin is critical for blood pressure regulation when cardiovascular homeostasis is threatened and some patients with shock have inappropriately low levels of hormone in plasma. The present review focuses on recent work that addresses the role of endogenous vasopressin in the pathogenesis of shock and the potential therapeutic indications and secondary effects of exogenous hormone in patients with shock. RECENT
FINDINGS: Examples of types of shock resistant to catecholamine pressors in which exogenous vasopressin was effective in restoring arterial pressure continued to accumulate. Widespread determinations of plasma vasopressin in patients with shock suggest that endogenous vasopressin deficiency may be more frequent than previously thought. The generation of mice with deletion of vasopressin's V1a receptor highlighted the important role of the hormone on cardiovascular homeostasis.
SUMMARY: Vasopressin administration is very effective in restoring arterial pressure in many forms of shock and this appears to be due, at least in part, to deficiency of endogenous hormone. Generation of mice lacking vasopressin V1a receptor open new and exciting avenues of inquiry to clarify the role of the hormone in cardiovascular homeostasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17599006     DOI: 10.1097/MCC.0b013e3282435e16

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  6 in total

1.  Multiple alpha1-adrenergic receptor subtypes support synergistic stimulation of vasopressin and oxytocin release by ATP and phenylephrine.

Authors:  Zhilin Song; Dayane A Gomes; Wanida Stevens; Celia D Sladek
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-09-29       Impact factor: 3.619

2.  Effect of Low-Dose Supplementation of Arginine Vasopressin on Need for Blood Product Transfusions in Patients With Trauma and Hemorrhagic Shock: A Randomized Clinical Trial.

Authors:  Carrie A Sims; Daniel Holena; Patrick Kim; Jose Pascual; Brian Smith; Neils Martin; Mark Seamon; Adam Shiroff; Shariq Raza; Lewis Kaplan; Elena Grill; Nicole Zimmerman; Christopher Mason; Benjamin Abella; Patrick Reilly
Journal:  JAMA Surg       Date:  2019-11-01       Impact factor: 14.766

3.  The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*.

Authors:  Marc O Maybauer; Dirk M Maybauer; Perenlei Enkhbaatar; Régent Laporte; Halina Wiśniewska; Lillian D Traber; ChiiDean Lin; Juanjuan Fan; Hal K Hawkins; Robert A Cox; Kazimierz Wiśniewski; Claudio D Schteingart; Donald W Landry; Pierre J-M Rivière; Daniel L Traber
Journal:  Crit Care Med       Date:  2014-07       Impact factor: 7.598

4.  Sustained stimulation of vasopressin and oxytocin release by ATP and phenylephrine requires recruitment of desensitization-resistant P2X purinergic receptors.

Authors:  Dayane A Gomes; Zhilin Song; Wanida Stevens; Celia D Sladek
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-07-22       Impact factor: 3.619

5.  Supplemental arginine vasopressin during the resuscitation of severe hemorrhagic shock preserves renal mitochondrial function.

Authors:  Carrie A Sims; Guan Yuxia; Khushboo Singh; Evan C Werlin; Patrick M Reilly; Joseph A Baur
Journal:  PLoS One       Date:  2017-10-24       Impact factor: 3.240

6.  Copeptin concentration following cardiac surgery as a prognostic marker of postoperative acute kidney injury: a prospective cohort study.

Authors:  Keigo Yamashita; Takehisa Abe; Yoshihiro Hayata; Tomoaki Hirose; Shun Hiraga; Ryohei Fukuba; Junichi Takemura; Rei Tonomura; Kazuki Yamamoto; Shinya Yokoyama; Shigeki Taniguchi
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.